Share

    


Home / Search Results

Search Results

You searched for:

In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
Put yourself first: this mantra is especially important today as we continue to grapple with the implications and fallout from the COVID-19 global pandemic.
Cancer programs are facing multiple challenges related to treating patients in a COVID-19 environment. Cancer programs need to deploy systems and processes to help navigate these patients into the healthcare system and to work through the backlog of new patients with cancer as quickly as possible within existing resources.
As we turn the corner toward 2022, for oncology to drive equity forward: We need every member and every discipline, patient, leader, payer, industry partner, and innovator working together to provide the most equitable care possible in a sustainable way.
Many times, being present, allowing the grief, and letting our patients know they aren’t alone is the only “treatment” we have. So, what sustains us? How do we do this every day?
Rather than fielding its annual Trending Now in Cancer Care survey while cancer programs were experiencing unprecedented challenges due to the extended public health emergency, ACCC chose to facilitate conversations with its members to capture the lived experiences of the most pertinent issues impacting oncology practice and care delivery.
Key results from a national survey show a range of new initiatives.
The overall cancer rate among adolescents and young adults is on a gradual increase, thus creating the need for oncology programs geared towards young adults and adolescents.
Presbyterian Healthcare Services developed a unique service, offering patients with cancer certain clinical interventions and wellness checks in the comfort of their home that is provided by the Albuquerque Ambulance Service Mobile Integrated Health team.
Because oral anti-cancer agents are most often administered outside of the clinic setting, it takes a multidisciplinary team to successfully manage these patients and their treatments.